Countries across Europe suspend use of AstraZeneca COVID-19 vaccine over blood clot fears
European Medicines Agency (EMA) has recommended Moderna coronavirus vaccine for use in the European Union amid growing criticism of the slow vaccination process across the EU.
«The Commission on Medicinal Products for Human (CHM) has carefully assessed the evidence on the quality, safety and efficacy of the vaccine for humans and, based on consensus, recommended that the European Commission issue a formal conditional marketing authorization.», – EMA said in a statement.
«With approval With the European Medicines Agency Moderna Vaccines, we are moving closer to our goal of having a portfolio of safe and effective COVID-19 vaccines. EU Commission approval to follow soon», – the EU health commissioner tweeted Stella Kyriakides (Stella Kyriakides).
Emer cook (Emer Cooke), executive director of the Amsterdam-based EMA, added that the Moderna vaccine «provides us with another tool to deal with the current emergency». This enables the European Commission, the EU’s executive body, to follow suit..
The Moderna vaccine is the second to receive the green light from European regulatory agencies. Vaccinations with this drug have already started in the UK and the US, where the vaccine had previously been approved..
Some lawmakers have raised concerns that the EU is too slow to distribute coronavirus vaccines to its citizens.
The use of vaccines against Covid-19 varies by block. France reported 516 vaccinations in the first week of its introduction, while Germany had about 240,000 vaccinations as of Sunday. The Netherlands has not yet begun to vaccinate people against coronavirus.
In addition, questions arise as to whether sufficient vaccine has been procured by the European Union..
A number of officials asked the European Commission, the EU’s executive body, to explain why it did not buy more injections.
A spokesman for the European Commission said on Monday that the institution «very focused on ensuring that our strategy is implemented perfectly».
Moderna shares slightly higher pre-sale amid this announcement.